Kevine SILIHE KAMGA

Dr. Kevine SILIHE KAMGA

Université de Yaoundé I, Yaoundé, Centre, Cameroon
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
SZStephane Zingue
Stephane Zingue
JCJulia Cisilotto
Julia Cisilotto
ATAlain Brice Tueche
Alain Brice Tueche
Anupam BishayeeAnupam Bishayee
Anupam Bishayee
FMFrancine Azegha Mefegue
Francine Azegha Mefegue
DNDieudonné NJamen
Dieudonné NJamen

Verified
Journal Article
Open access
PDF file
Kevine SILIHE KAMGAKevine SILIHE KAMGA
Kevine SILIHE KAMGA
SZStephane Zingue
Stephane Zingue
EWEvelyn Winter
Evelyn Winter
AFAwounfack charline Florence
Awounfack charline Florence
Anupam BishayeeAnupam Bishayee
Anupam Bishayee
TCTania Creczynski-Pasa
Tania Creczynski-Pasa
A Ficus umbellata is used to treat cancer. The present work was therefore designed to assess antitumor potentials of F. umbellata extracts in nine different cell lines. Cell cycle, apoptosis, cell migration/invasion, levels of reactive oxygen species (ROS), mitochondrial membrane potential (MMP), caspases activities as well as Bcl-2 and Bcl-xL protein content were assessed in MDA-MB-231 cells. The 7,12-dimethylbenz(a)anthracene (DMBA)-induced carcinogenesis in rats were also used to investigate antitumor potential of F. umbellata extracts. The F. umbellata methanol extract exhibited a CC50 of 180 μg/mL in MDA-MB-231 cells after 24 h. It induced apoptosis in MCF-7 and MDA-MB-231 cells, while it did not alter their cell cycle phases. Further, it induced a decrease in MMP, an increase in ROS levels and caspases activities as well as a downregulation in Bcl-2 and Bcl-xL protein contents in MDA-MB-231 cells. In vivo, F. umbellata aqueous (200 mg/kg) and methanol (50 mg/kg) extracts significantly (p < 0.001) reduced ovarian tumor incidence (10%), total tumor burden (58% and 46%, respectively), average tumor weight (57.8% and 45.6%, respectively) as compared to DMBA control group. These results suggest antitumor potential of F. umbellata constituents possibly due to apoptosis induction mediated through ROS-dependent mitochondrial pathway.

1 January 2022 in Arabian Journal of Chemistry
Verified
Journal Article
Open access
MKMichael H.K. Kamdem
Michael H.K. Kamdem
OOOlusesan Ojo
Olusesan Ojo
BKBlondelle M. Kemkuignou
Blondelle M. Kemkuignou
RTRostan M. Talla
Rostan M. Talla
TFThierry Y. Fonkui
Thierry Y. Fonkui
DNDerek T. Ndinteh
Derek T. Ndinteh

24 March 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
SFSorelle Ines Fotsing
Sorelle Ines Fotsing
JPJudith Christiane Ngo Pambe
Judith Christiane Ngo Pambe
Kevine SILIHE KAMGAKevine SILIHE KAMGA
Kevine SILIHE KAMGA
NYNatacha Lena Yembeau
Natacha Lena Yembeau
ACArmand Choupo
Armand Choupo
SZStephane Zingue
Stephane Zingue

22 September 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
MCMartin Chrastina
Martin Chrastina
FDFrantisek Drafi
Frantisek Drafi
KPKatarína Pružinská
Katarína Pružinská
CSCentre of Experimental Medicine Slovak Academy Sciences
Centre of Experimental Medicine Slovak Academy Sciences
Kevine SILIHE KAMGAKevine SILIHE KAMGA
Kevine SILIHE KAMGA
Katarina BauerovaKatarina Bauerova
Katarina Bauerova
Rheumatoid arthritis (RA), an autoimmune disease, is characterized by inflammation that affects not only the liver but also other organs and the musculoskeletal system. The standard therapy for RA is methotrexate (MTX), which has safety limitations. The extract from Crocus sativus L. (saffron—SF) is also known for its anti-inflammatory effects. Therefore, we decided to investigate the potential benefit of SF in monotherapy via two doses (SF1—25 mg/kg of b.w.; SF2—50 mg/kg of b.w.) and in combination with MTX (0.3 mg/kg of b.w., twice a week) using adjuvant arthritis in rats. To evaluate these therapeutic settings, we used biometric, immunological, and biochemical parameters, as well as the relative gene expression of the mRNA in the liver. Our results showed a statistically significant increase in the experimental animals’ body weight and the arthritic score (AS) on day 14 for monotherapy with SF1 and SF2. The change of hind paw volume (CHPV) was significant only for SF2 monotherapy on the 14th day of the experiment. A combination of SF1 and SF2 with MTX significantly modulated all the biometric parameters during the experimental period. Additionally, AS and CHPV improved considerably compared to MTX monotherapy on day 21. Furthermore, all monotherapies and combination therapies were significant for the biochemical parameter γ-glutamyl transferase (GGT) in the joint. GGT activity in the spleen was less pronounced; only MTX in combination with SF1 significantly modified this parameter. The higher dose of SF monotherapy (SF2) was similarly significant with respect to immunological parameters, such as plasmatic IL-17A, IL-1β, and MMP-9 on day 21. The combination of both doses of SF with MTX significantly improved these immunological parameters, except for C-reactive protein (CRP), which was influenced only by the higher dose of SF2 in combination with MTX in plasma at the end of the experiment. A different effect was found for the relative expression of CD36 mRNA, where only SF1 significantly decreased gene expression in the liver. However, the relative gene mRNA expression of IL-1β in the liver was significantly reduced by the SF monotherapies and the combination of both SF doses with MTX. Our findings showed SF’s partial antiarthritic and anti-inflammatory potential in monotherapy, but the effect was stronger in combination with MTX.

7 April 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
SZStephane Zingue
Stephane Zingue
Kevine SILIHE KAMGAKevine SILIHE KAMGA
Kevine SILIHE KAMGA
IBInnocent Fouba Bourfane
Innocent Fouba Bourfane
ABAli Boukar
Ali Boukar
ATAlain Brice Tueche
Alain Brice Tueche
DNDieudonné NJamen
Dieudonné NJamen
Neem (Azadirachta indica) is a tree from the Meliaceae family native to India, where it is considered as one of the most important plants worldwide. The anticancer effects of neem oil on breast cancer cells have been recently reported; however, its in vivo effects have not been studied. This prompted us to investigate the protective effects of neem oil on 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer in high-fat/sucrose-fed Wistar rats. Juvenile female Wistar rats were treated either with neem oil at a dose of 3 mL/kg body weight at 3 different frequencies, 2 times/week (Neem 1), 4 times/week (Neem 2), and every day (Neem 3), or with tamoxifen (3.3 mg/kg body weight), starting 1 week prior to DMBA treatment and lasting 12 weeks. Incidence, burden, volume, and histological analysis of mammary tumors were measured. Further toxicological parameters have been assessed. No tumors were detected in rats from the normal group, while all the rats from the negative control group (100%) developed mammary tumors. The regular consumption of neem oil at a dose of 3 mL/kg (2 or 4 times/week) significantly (p < 0.01) and in a dose-dependent manner reduced tumor incidence (80%), burden [35.78% (2 times/week) and 36.09% (4 times/week)], and weight. Neem consumption protected rats against DMBA-induced breast hyperplasia, with an optimal effect when taken 4 times weekly. Interestingly, all the animals that received a daily dose of 3 mL/kg died at the third week of the experiment. Further, animals that took the neem oil 4 times per week developed hepatotoxicity, evidenced by an increase of liver wet weight, transaminase (ALT and AST) activity, and histological abnormalities in liver. This study brings insight into the use of neem oil, which is greatly appreciated in traditional medicine. In summary, we demonstrated for the first time that the regular consumption of neem oil prevents breast cancer, but its excessive consumption is toxic.